White Paper

Streamlining ADC Development: Advantage Of An All-In-One Solution

Source: Eurofins
GettyImages-673804426 aseptic biologics clean room lab

Antibody-drug conjugates (ADCs) offer targeted cancer treatment by combining monoclonal antibodies with cytotoxic payloads via specialized linkers. While therapeutically promising, ADC production is complex, involving biologics manufacturing, synthesis of highly potent active pharmaceutical ingredients (HPAPIs), and precise conjugation—all of which pose logistical, technical, and regulatory challenges. Traditional outsourcing to multiple contract development and manufacturing organizations (CDMOs) often results in fragmented supply chains, inconsistent quality control, and delays due to coordination hurdles across sites.

A fully integrated manufacturing model addresses these issues by consolidating ADC production—including monoclonal antibody (mAb) development, HPAPI synthesis, conjugation, and fill-finish—within a single campus. This eliminates intermediate transfers, reducing the risk of contamination, variability, and project delays. Key advantages of the integrated approach include streamlined communication, centralized quality assurance, real-time troubleshooting, and faster project turnaround times.

Advanced analytical capabilities are essential due to ADCs’ structural complexity. Specialized techniques like chromatography and mass spectrometry are required to assess drug-to-antibody ratios, aggregation, and stability. Manufacturing technologies such as single-use systems and isolators further enhance safety, prevent cross-contamination, and maintain product integrity.

As the ADC market grows—projected to surpass $30 billion by 2028—streamlined, high-quality manufacturing is critical for pharmaceutical companies to meet clinical and commercial demands efficiently. Centralized solutions, built on expertise in both biologics and small molecule production, help reduce time-to-market, improve consistency, and ensure regulatory compliance. This integrated model positions providers to meet rising demand while delivering precision oncology therapies with greater efficiency and reliability.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma